DME Scammer Prevention Act of 2026
Summary
The DME Scammer Prevention Act of 2026 (HR8871) is an early-stage bill referred to two committees. It mandates electronic submission and a 90-day filing deadline for certain DME claims under Medicare. No funding is authorized, and the bill is procedural with no direct market impact on any publicly traded company at this stage.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.HR8871 is an early-stage procedural bill with no funding or direct market impact.
- 2.No publicly traded company is uniquely affected; compliance costs are immaterial.
- 3.Investors should monitor committee action but no actionable trade signal exists.
Market Implications
No market implications at this stage. The bill is purely administrative and does not affect any sector's revenue or cost structure. Investors should ignore until committee action indicates momentum.
Full Analysis
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
Executive Order: Promoting Efficiency, Accountability, and Performance in Federal Contracting
DELL FEDERAL SYSTEMS L.P: $602M Department of Veterans Affairs Contract
OPTUM PUBLIC SECTOR SOLUTIONS, INC.: $1.1B Department of Veterans Affairs Contract
American Innovation and R&D Competitiveness Act of 2025
Executive Order: Integrating Financial Technology Innovation into Regulatory Frameworks
Executive Order: Accelerating Medical Treatments for Serious Mental Illness
ADVANCED TECHNOLOGY INTERNATIONAL: $304M Department of Health and Human Services Contract
Protecting Health Care and Lowering Costs Act of 2025
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Integrating Financial Technology Innovation into Regulatory Frameworks
This executive order directs federal financial regulators to review and streamline regulations that hinder fintech innovation, particularly for small and emerging firms, and requests the Federal Reserve to evaluate expanding access to its payment accounts and services for non-bank and digital asset firms. It aims to reduce barriers to entry and encourage partnerships between fintech firms and traditional financial institutions, with specific deadlines for reviews and reports.
Promoting Efficiency, Accountability, and Performance in Federal Contracting
This executive order mandates that federal agencies default to using fixed-price contracts for procurement, shifting away from cost-reimbursement models. It requires written justification and senior-level approval for any non-fixed-price contract over certain dollar thresholds (e.g., $10M for most agencies, $100M for the Department of War), and directs agencies to review and renegotiate their 10 largest non-fixed-price contracts within 90 days. The order also tasks OMB with implementation guidance and the Federal Acquisition Regulatory Council with proposing regulatory amendments within 120 days.
Accelerating Medical Treatments for Serious Mental Illness
This executive order directs the FDA to prioritize review and facilitate 'Right to Try' access for psychedelic drugs, including ibogaine compounds, that have received Breakthrough Therapy designation for serious mental illnesses. It also allocates $50 million from HHS to support state programs advancing these treatments and mandates collaboration between HHS, FDA, VA, and the private sector to increase clinical trial participation and data sharing for these drugs. The Attorney General is further directed to expedite rescheduling reviews for approved Schedule I psychedelic substances.